US20060058339A1 - Compounds modulating c-kit activity and uses therefor - Google Patents
Compounds modulating c-kit activity and uses therefor Download PDFInfo
- Publication number
- US20060058339A1 US20060058339A1 US11/154,287 US15428705A US2006058339A1 US 20060058339 A1 US20060058339 A1 US 20060058339A1 US 15428705 A US15428705 A US 15428705A US 2006058339 A1 US2006058339 A1 US 2006058339A1
- Authority
- US
- United States
- Prior art keywords
- kit
- compound
- cells
- binding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GMBNOLPTHRSLSY-UHFFFAOYSA-N CC1=CC=C(CNC2=NC=C(CC3=CNC4=C3C=CC=N4)C=C2)C=C1 Chemical compound CC1=CC=C(CNC2=NC=C(CC3=CNC4=C3C=CC=N4)C=C2)C=C1 GMBNOLPTHRSLSY-UHFFFAOYSA-N 0.000 description 6
- AMDMKMUQDNWBOJ-UHFFFAOYSA-N ClC1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 Chemical compound ClC1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 AMDMKMUQDNWBOJ-UHFFFAOYSA-N 0.000 description 2
- DVMGTZRHKQYIBK-UHFFFAOYSA-N FC1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 Chemical compound FC1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 DVMGTZRHKQYIBK-UHFFFAOYSA-N 0.000 description 2
- BNGOFGAYJFGOEV-UHFFFAOYSA-N C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1.CC(C)[Si](C(C)C)(C(C)C)N1C=C(CC2=CN=C(Cl)C=C2)C2=CC=CN=C21.CC(C)[Si](C(C)C)(C(C)C)N1C=C(CC2=CN=C(NCC3=CC=CC=C3)C=C2)C2=CC=CN=C21 Chemical compound C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1.CC(C)[Si](C(C)C)(C(C)C)N1C=C(CC2=CN=C(Cl)C=C2)C2=CC=CN=C21.CC(C)[Si](C(C)C)(C(C)C)N1C=C(CC2=CN=C(NCC3=CC=CC=C3)C=C2)C2=CC=CN=C21 BNGOFGAYJFGOEV-UHFFFAOYSA-N 0.000 description 1
- KMEMSLMHGYEOFZ-UHFFFAOYSA-N C1=CN=C2NC=CC2=C1.CC1=NC=C(CC2=CN(C)C3=NC=CC=C23)C=C1.CN(C)CC1=CN(C)C2=NC=CC=C12.CN(C)CC1=CNC2=NC=CC=C12.CN1C=C(CCl)C2=CC=CN=C21 Chemical compound C1=CN=C2NC=CC2=C1.CC1=NC=C(CC2=CN(C)C3=NC=CC=C23)C=C1.CN(C)CC1=CN(C)C2=NC=CC=C12.CN(C)CC1=CNC2=NC=CC=C12.CN1C=C(CCl)C2=CC=CN=C21 KMEMSLMHGYEOFZ-UHFFFAOYSA-N 0.000 description 1
- IWQYCRGZCJYCFR-UHFFFAOYSA-N C1=CN=C2NC=CC2=C1.O=C(C1=CC=C(Cl)N=C1)C1=CNC2=NC=CC=C12.O=C(Cl)C1=CC=C(Cl)N=C1 Chemical compound C1=CN=C2NC=CC2=C1.O=C(C1=CC=C(Cl)N=C1)C1=CNC2=NC=CC=C12.O=C(Cl)C1=CC=C(Cl)N=C1 IWQYCRGZCJYCFR-UHFFFAOYSA-N 0.000 description 1
- SLGBTOVWILTNHZ-UHFFFAOYSA-N C1CNC2NCCC2C1 Chemical compound C1CNC2NCCC2C1 SLGBTOVWILTNHZ-UHFFFAOYSA-N 0.000 description 1
- SJVKCTUFJQTQTI-UHFFFAOYSA-N FC(F)(F)C1=CC=C(CNC2=CC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 Chemical compound FC(F)(F)C1=CC=C(CNC2=CC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1 SJVKCTUFJQTQTI-UHFFFAOYSA-N 0.000 description 1
- QCRPPQATLBGXIP-UHFFFAOYSA-N FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1.O=C(C1=CC=C(Cl)N=C1)C1=CNC2=NC=CC=C12.O=C(C1=CN=C(NCC2=CC=C(C(F)(F)F)C=C2)C=C1)C1=CNC2=NC=CC=C12.OC(C1=CN=C(NCC2=CC=C(C(F)(F)F)C=C2)C=C1)C1=CNC2=NC=CC=C12 Chemical compound FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C34)C=C2)C=C1.O=C(C1=CC=C(Cl)N=C1)C1=CNC2=NC=CC=C12.O=C(C1=CN=C(NCC2=CC=C(C(F)(F)F)C=C2)C=C1)C1=CNC2=NC=CC=C12.OC(C1=CN=C(NCC2=CC=C(C(F)(F)F)C=C2)C=C1)C1=CNC2=NC=CC=C12 QCRPPQATLBGXIP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/154,287 US20060058339A1 (en) | 2004-06-17 | 2005-06-16 | Compounds modulating c-kit activity and uses therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58089804P | 2004-06-17 | 2004-06-17 | |
US68205805P | 2005-05-17 | 2005-05-17 | |
US68207605P | 2005-05-17 | 2005-05-17 | |
US11/154,287 US20060058339A1 (en) | 2004-06-17 | 2005-06-16 | Compounds modulating c-kit activity and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060058339A1 true US20060058339A1 (en) | 2006-03-16 |
Family
ID=35262233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/154,287 Abandoned US20060058339A1 (en) | 2004-06-17 | 2005-06-16 | Compounds modulating c-kit activity and uses therefor |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060058339A1 (ja) |
EP (1) | EP1755597A2 (ja) |
JP (1) | JP2008503473A (ja) |
AU (1) | AU2005265017A1 (ja) |
CA (1) | CA2570817A1 (ja) |
PA (1) | PA8637601A1 (ja) |
SV (1) | SV2005002148A (ja) |
TW (1) | TW200616632A (ja) |
WO (2) | WO2006009755A2 (ja) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058340A1 (en) * | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity |
US20070032519A1 (en) * | 2005-05-17 | 2007-02-08 | Chao Zhang | Compounds modulating c-kit and c-fms activity and uses therefor |
US20080167338A1 (en) * | 2006-12-21 | 2008-07-10 | Wayne Spevak | Compounds and methods for kinase modulation, and indications therefor |
US20080188514A1 (en) * | 2006-12-21 | 2008-08-07 | Guoxian Wu | Compounds and methods for kinase modulation, and indications therefor |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20090076046A1 (en) * | 2006-11-22 | 2009-03-19 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US20100249118A1 (en) * | 2005-06-22 | 2010-09-30 | Ibrahim Prabha N | Compounds and methods for kinase modulation, and indications therefor |
US20100310659A1 (en) * | 2009-04-03 | 2010-12-09 | Plexxikon, Inc. | Compositions and Uses Thereof |
US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9260437B2 (en) | 2008-05-19 | 2016-02-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9440969B2 (en) | 2009-12-23 | 2016-09-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9550768B2 (en) | 2011-05-17 | 2017-01-24 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9617267B2 (en) | 2009-11-18 | 2017-04-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9682981B2 (en) | 2010-04-21 | 2017-06-20 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9718847B2 (en) | 2013-03-15 | 2017-08-01 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771363B2 (en) | 2015-09-21 | 2017-09-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9822109B2 (en) | 2013-03-15 | 2017-11-21 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9873700B2 (en) | 2013-05-30 | 2018-01-23 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
US10435404B2 (en) | 2017-07-25 | 2019-10-08 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10508085B2 (en) | 2016-09-22 | 2019-12-17 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11103505B2 (en) | 2017-10-27 | 2021-08-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
CN113975386A (zh) * | 2014-05-23 | 2022-01-28 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101298967B1 (ko) | 2004-03-30 | 2013-09-02 | 버텍스 파마슈티칼스 인코포레이티드 | Jak 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
EP1973911B1 (en) | 2006-01-17 | 2016-01-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful for the treatment of (inter alia) proliferative, cardiac, neurodegenerative, autoimmune or inflammatory disorders |
CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
JP5767965B2 (ja) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
DK3141252T3 (en) | 2009-06-17 | 2018-11-19 | Vertex Pharma | INHIBITORS OF INFLUENZA VIRUS REPLICATION |
BR112012003462A2 (pt) | 2009-08-24 | 2016-02-23 | Ascepion Pharmaceuticals Inc | "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase." |
US20120076797A1 (en) * | 2010-07-14 | 2012-03-29 | Butte Atul J | Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation |
CA2822057A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
WO2015006754A2 (en) | 2013-07-11 | 2015-01-15 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
MX2016006199A (es) | 2013-11-13 | 2016-08-08 | Vertex Pharma | Inhibidores de replicacion del virus de influenza. |
EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
US11274108B2 (en) * | 2015-07-20 | 2022-03-15 | Genzyme Corporation | Colony stimulating factor-1 receptor (CSF-1R) inhibitors |
RU2018115334A (ru) | 2015-10-09 | 2019-11-11 | Ацея Терапьютикс, Инк. | Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения |
MA46716A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
JP2020516682A (ja) | 2017-04-07 | 2020-06-11 | エイシア セラピューティクス, インコーポレイテッド | ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法 |
CN111201438A (zh) | 2017-06-02 | 2020-05-26 | 朱诺治疗学股份有限公司 | 与和细胞疗法相关的毒性有关的制品和方法 |
CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
AU2019387494A1 (en) | 2018-11-30 | 2021-06-10 | Juno Therapeutics, Inc. | Methods for dosing and treatment of B cell malignancies in adoptive cell therapy |
WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
BR112021019050A2 (pt) | 2019-03-29 | 2021-11-30 | Kowa Company Ltd | Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto |
WO2021113770A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CN111233857B (zh) * | 2020-01-16 | 2021-01-08 | 河南应用技术职业学院 | 一种连续化生产培西达替尼的合成方法 |
IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
JP2024500919A (ja) | 2020-12-23 | 2024-01-10 | ジェンザイム・コーポレーション | 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤 |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150949A (en) * | 1976-04-15 | 1979-04-24 | Technicon Instruments Corporation | Immunoassay for gentamicin |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5338849A (en) * | 1992-02-14 | 1994-08-16 | Lipha, Lyonnaise Industrielle Pharmaceutique | Azaindoles, preparation processes and medicinal products containing them |
US5432177A (en) * | 1993-03-01 | 1995-07-11 | Merck Sharpe & Dohme Ltd. | Pyrrolo-pyridine derivatives |
US5434049A (en) * | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5681959A (en) * | 1995-02-21 | 1997-10-28 | Merck, Sharp & Dohme Ltd. | Chemical synthesis of azaindoles |
US5700809A (en) * | 1993-03-01 | 1997-12-23 | Merck Sharp & Dohme, Ltd. | Pyrrolo-pyridine derivatives |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5744305A (en) * | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5770456A (en) * | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5877007A (en) * | 1988-02-10 | 1999-03-02 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5959098A (en) * | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6022963A (en) * | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US6243980B1 (en) * | 1997-03-07 | 2001-06-12 | Tropix, Inc. | Protease inhibitor assay |
US20010008765A1 (en) * | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20010012537A1 (en) * | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US20010014448A1 (en) * | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
US20010014449A1 (en) * | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US6277628B1 (en) * | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010016322A1 (en) * | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US20010018642A1 (en) * | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
US20010019827A1 (en) * | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US6545014B2 (en) * | 1996-04-15 | 2003-04-08 | Texas Biotechnology Corporation | Method of treating glaucoma |
US20040002534A1 (en) * | 1999-12-22 | 2004-01-01 | Sugen, Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20050256151A1 (en) * | 2003-12-24 | 2005-11-17 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20070049615A1 (en) * | 2003-12-19 | 2007-03-01 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
GB9420521D0 (en) * | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
JP2003518123A (ja) * | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | 4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
-
2005
- 2005-06-16 WO PCT/US2005/021231 patent/WO2006009755A2/en active Application Filing
- 2005-06-16 US US11/154,287 patent/US20060058339A1/en not_active Abandoned
- 2005-06-16 AU AU2005265017A patent/AU2005265017A1/en not_active Abandoned
- 2005-06-16 EP EP05789913A patent/EP1755597A2/en not_active Withdrawn
- 2005-06-16 WO PCT/US2005/021360 patent/WO2006009797A1/en active Application Filing
- 2005-06-16 CA CA002570817A patent/CA2570817A1/en not_active Abandoned
- 2005-06-16 TW TW094120055A patent/TW200616632A/zh unknown
- 2005-06-16 JP JP2007516717A patent/JP2008503473A/ja active Pending
- 2005-06-17 SV SV2005002148A patent/SV2005002148A/es not_active Application Discontinuation
- 2005-06-17 PA PA20058637601A patent/PA8637601A1/es unknown
Patent Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150949A (en) * | 1976-04-15 | 1979-04-24 | Technicon Instruments Corporation | Immunoassay for gentamicin |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
US5877007A (en) * | 1988-02-10 | 1999-03-02 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6261776B1 (en) * | 1989-06-07 | 2001-07-17 | Affymetrix, Inc. | Nucleic acid arrays |
US5770456A (en) * | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744305A (en) * | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5338849A (en) * | 1992-02-14 | 1994-08-16 | Lipha, Lyonnaise Industrielle Pharmaceutique | Azaindoles, preparation processes and medicinal products containing them |
US5434049A (en) * | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
US5432177A (en) * | 1993-03-01 | 1995-07-11 | Merck Sharpe & Dohme Ltd. | Pyrrolo-pyridine derivatives |
US5700809A (en) * | 1993-03-01 | 1997-12-23 | Merck Sharp & Dohme, Ltd. | Pyrrolo-pyridine derivatives |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US20010014449A1 (en) * | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5681959A (en) * | 1995-02-21 | 1997-10-28 | Merck, Sharp & Dohme Ltd. | Chemical synthesis of azaindoles |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US6022963A (en) * | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6545014B2 (en) * | 1996-04-15 | 2003-04-08 | Texas Biotechnology Corporation | Method of treating glaucoma |
US5959098A (en) * | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6258606B1 (en) * | 1996-07-09 | 2001-07-10 | Nanogen, Inc. | Multiplexed active biologic array |
US6243980B1 (en) * | 1997-03-07 | 2001-06-12 | Tropix, Inc. | Protease inhibitor assay |
US20010018642A1 (en) * | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
US20010019827A1 (en) * | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US20010014448A1 (en) * | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6277628B1 (en) * | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010016322A1 (en) * | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US20010012537A1 (en) * | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) * | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20040002534A1 (en) * | 1999-12-22 | 2004-01-01 | Sugen, Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US20070049615A1 (en) * | 2003-12-19 | 2007-03-01 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
US20050256151A1 (en) * | 2003-12-24 | 2005-11-17 | Pharmacia Italia S.P.A. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
US20060058340A1 (en) * | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity |
US7947708B2 (en) | 2004-06-17 | 2011-05-24 | Plexxikon, Inc. | Compounds modulating C-kit activity |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US20090105297A1 (en) * | 2004-06-17 | 2009-04-23 | Plexxikon Inc | Compounds Modulating C-Kit Activity |
US20070032519A1 (en) * | 2005-05-17 | 2007-02-08 | Chao Zhang | Compounds modulating c-kit and c-fms activity and uses therefor |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
US20110166174A1 (en) * | 2005-05-17 | 2011-07-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
US8415469B2 (en) | 2005-06-22 | 2013-04-09 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20100249118A1 (en) * | 2005-06-22 | 2010-09-30 | Ibrahim Prabha N | Compounds and methods for kinase modulation, and indications therefor |
US20100256365A1 (en) * | 2005-06-22 | 2010-10-07 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8470818B2 (en) | 2005-06-22 | 2013-06-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20110059963A1 (en) * | 2005-06-22 | 2011-03-10 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7893075B2 (en) | 2006-11-22 | 2011-02-22 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US8722702B2 (en) | 2006-11-22 | 2014-05-13 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US20090076046A1 (en) * | 2006-11-22 | 2009-03-19 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US8404700B2 (en) | 2006-11-22 | 2013-03-26 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US8461169B2 (en) | 2006-11-22 | 2013-06-11 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity |
US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US7863289B2 (en) | 2006-12-21 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20110092538A1 (en) * | 2006-12-21 | 2011-04-21 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8268858B2 (en) | 2006-12-21 | 2012-09-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20080188514A1 (en) * | 2006-12-21 | 2008-08-07 | Guoxian Wu | Compounds and methods for kinase modulation, and indications therefor |
US20080167338A1 (en) * | 2006-12-21 | 2008-07-10 | Wayne Spevak | Compounds and methods for kinase modulation, and indications therefor |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10426760B2 (en) | 2007-07-17 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20100190777A1 (en) * | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9844539B2 (en) | 2007-07-17 | 2017-12-19 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9260437B2 (en) | 2008-05-19 | 2016-02-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US20100310659A1 (en) * | 2009-04-03 | 2010-12-09 | Plexxikon, Inc. | Compositions and Uses Thereof |
US9663517B2 (en) | 2009-04-03 | 2017-05-30 | Plexxikon Inc. | Compositions and uses thereof |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9617267B2 (en) | 2009-11-18 | 2017-04-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9440969B2 (en) | 2009-12-23 | 2016-09-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9682981B2 (en) | 2010-04-21 | 2017-06-20 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11337976B2 (en) | 2011-02-07 | 2022-05-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
US9550768B2 (en) | 2011-05-17 | 2017-01-24 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9730918B2 (en) | 2012-03-19 | 2017-08-15 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US10123998B2 (en) | 2012-03-19 | 2018-11-13 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9695169B2 (en) | 2012-05-31 | 2017-07-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10301280B2 (en) | 2012-12-21 | 2019-05-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9718847B2 (en) | 2013-03-15 | 2017-08-01 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9822109B2 (en) | 2013-03-15 | 2017-11-21 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9873700B2 (en) | 2013-05-30 | 2018-01-23 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US10421761B2 (en) | 2013-05-30 | 2019-09-24 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN113975386A (zh) * | 2014-05-23 | 2022-01-28 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10370374B2 (en) | 2015-09-21 | 2019-08-06 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771363B2 (en) | 2015-09-21 | 2017-09-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9975894B2 (en) | 2015-09-21 | 2018-05-22 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10647716B2 (en) | 2015-09-21 | 2020-05-12 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10899761B2 (en) | 2015-09-21 | 2021-01-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10508085B2 (en) | 2016-09-22 | 2019-12-17 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
US10941142B2 (en) | 2017-07-25 | 2021-03-09 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10961240B2 (en) | 2017-07-25 | 2021-03-30 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10435404B2 (en) | 2017-07-25 | 2019-10-08 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
US11103505B2 (en) | 2017-10-27 | 2021-08-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
Also Published As
Publication number | Publication date |
---|---|
PA8637601A1 (es) | 2006-06-02 |
WO2006009755A3 (en) | 2006-04-20 |
SV2005002148A (es) | 2005-12-09 |
EP1755597A2 (en) | 2007-02-28 |
WO2006009797A1 (en) | 2006-01-26 |
CA2570817A1 (en) | 2006-01-26 |
JP2008503473A (ja) | 2008-02-07 |
TW200616632A (en) | 2006-06-01 |
AU2005265017A1 (en) | 2006-01-26 |
WO2006009755A2 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060058339A1 (en) | Compounds modulating c-kit activity and uses therefor | |
US7947708B2 (en) | Compounds modulating C-kit activity | |
JP6113151B2 (ja) | キナーゼ調節およびその適応症 | |
US7211600B2 (en) | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds | |
US7846941B2 (en) | Compounds modulating c-kit and c-fms activity and uses therefor | |
EP1949902B1 (en) | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | |
US20090162286A1 (en) | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | |
KR20180033194A (ko) | 키랄 디아릴 매크로사이클 및 이것의 용도 | |
JPH11507355A (ja) | タンパク質チロシンキナーゼher−2の自己リン酸化能を選択的に阻害するアリール及びヘテロアリールキナゾリン化合物 | |
EA006604B1 (ru) | Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
US11040038B2 (en) | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same | |
JP2011516486A (ja) | 骨質量疾患の診断、予防、及び治療方法 | |
KR20020073176A (ko) | 불안증 개선 방법 | |
US7026343B2 (en) | Pharmacologic inhibition of Myc function | |
Steen et al. | Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy | |
US7148252B2 (en) | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | |
US20150065486A1 (en) | Methods for treating polycystic kidney disease | |
TWI554502B (zh) | 受體型激酶調節劑及治療多囊性腎疾病的方法 | |
US8933037B2 (en) | Methods involving PDGFRBETA inhibitors | |
CN117479939A (zh) | 用于治疗红细胞增多症的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PLEXXIKON, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IBRAHIM, PRABHA N.;HURT, CLARENCE R.;ZHANG, CHAO;AND OTHERS;REEL/FRAME:016846/0128;SIGNING DATES FROM 20050718 TO 20051020 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |